N2001-02: I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2013 by Children's Hospital Los Angeles.
Recruitment status was  Active, not recruiting
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Nant Operations Center, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
First received: November 11, 2005
Last updated: February 21, 2013
Last verified: February 2013

November 11, 2005
February 21, 2013
September 2005
December 2012   (final data collection date for primary outcome measure)
Response (complete response, very good partial response, and partial response) at 60-days post stem cell infusion [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00253435 on ClinicalTrials.gov Archive Site
  • Event-free survival [ Designated as safety issue: No ]
  • Time to progression [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
N2001-02: I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine, may carry radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such as carboplatin, etoposide, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. An autologous peripheral stem cell or bone marrow transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Giving iodine I 131 metaiodobenzylguanidine and combination chemotherapy with an autologous peripheral stem cell or bone marrow transplant may allow more chemotherapy to be given so that more tumor cells are killed. Giving radiation therapy after an autologous peripheral stem cell or bone marrow transplant may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying how well giving iodine I 131 metaiodobenzylguanidine together with combination chemotherapy and radiation therapy works in treating patients who are undergoing an autologous peripheral stem cell or bone marrow transplant for relapsed or refractory neuroblastoma.



  • Determine the response rate in patients with relapsed or refractory neuroblastoma treated with iodine I 131 metaiodobenzylguanidine (^131I-MIBG) and combination chemotherapy comprising carboplatin, etoposide, and melphalan followed by autologous bone marrow or peripheral blood stem cell transplantation and radiotherapy.


  • Determine the hematopoietic and nonhematopoietic toxicity of this regimen in these patients.
  • Determine the tumor self-absorbed radiation dose (TSARD) in patients with measurable soft tissue lesions treated with this regimen.
  • Correlate the TSARD with tumor response in patients with measurable residual soft tissue disease treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified according to risk (poor-risk group [mixed or no response to induction therapy or progression during or after induction therapy] vs good-risk group [partial response after 4 courses of induction therapy]) and kidney function at study entry (glomerular filtration rate [GFR] ≥ 100 mL/min vs GFR 60-99 mL/min)

  • Stem cell harvest: Patients undergo a peripheral blood stem cell harvest or bone marrow harvest provided they have an adequate number of cells available. At least 2 weeks later, patients proceed to iodine I 131 metaiodobenzylguanidine (^131I-MIBG) and combination chemotherapy.
  • 131I-MIBG and combination chemotherapy: Patients receive ^131I-MIBG IV over 2 hours on day -21, carboplatin IV continuously on days -7 to -4, etoposide IV continuously on days -7 to -4, and melphalan IV over 1 hour on days -7 to -5.
  • Stem cell infusion and filgrastim (G-CSF): Three days after completion of chemotherapy, patients undergo transplantation of either stem cells or bone marrow on day 0. Patients also receive G-CSF subcutaneously or IV over 1 hour once daily beginning on day 0 and continuing until blood counts return to normal.
  • Radiotherapy: Once blood counts return to normal, patients undergo radiotherapy to primary and metastatic sites that have not received previous irradiation over 12 days beginning after day 42.

After completion of study treatment, patients are followed for 2 years and then periodically thereafter.

PROJECTED ACCRUAL: Approximately 50 patients (40 low-risk patients and 8-10 high-risk patients) will be accrued for this study.

Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Biological: filgrastim
  • Drug: carboplatin
  • Drug: etoposide
  • Drug: melphalan
  • Procedure: autologous bone marrow transplantation
  • Procedure: peripheral blood stem cell transplantation
  • Radiation: iobenguane I 131
  • Radiation: radiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
December 2012   (final data collection date for primary outcome measure)


  • Diagnosis of relapsed or refractory neuroblastoma

    • Histologically confirmed and/or demonstration of tumor cells in bone marrow with elevated urinary catecholamine metabolites
    • High-risk neuroblastoma must meet one of the following:

      • Progressive disease prior to or after completion of induction therapy
      • Mixed response or no response after completion of 4 courses of induction therapy
      • Partial response after 4 courses of induction therapy allowed provided no prior participation in COG-A3973 or other phase III COG trials
  • Measurable disease, defined as at least one metaiodobenzylguanidine (MIBG)-avid target lesion determined by diagnostic MIBG scan within 6 weeks of study entry (tumor sites that have received local irradiation within 3 months of study entry are not considered target lesions)


Performance status

  • Lansky 60-100% OR
  • Karnofsky 60-100%

Life expectancy

  • At least 2 months


  • Hemoglobin ≥ 10 g/dL
  • Absolute neutrophil count ≥ 750/mm^3
  • Platelet count ≥ 50,000/mm^3 (if no marrow involvement by morphologic exam/no transfusion allowed) (> 20,000/mm^3 if metastatic tumor involvement of marrow by morphologic exam/transfusion allowed)


  • Bilirubin < 1.3 mg/dL
  • SGOT and SGPT < 5 times normal
  • Hepatitis B surface antigen negative
  • Hepatitis C negative


  • Glomerular filtration rate or creatinine clearance ≥ 60 ml/min
  • Creatinine ≤ 1.5 times normal for age as follows:

    • 0.8 mg/dL (for patients ≤ 5 years of age)
    • 1.0 mg/dL (for patients 6 to 10 years of age)
    • 1.2 mg/dL (for patients 11 to 15 years of age)
    • 1.5 mg/dL (for patients > 15 years of age)


  • Ejection fraction ≥ 55% by echocardiogram or radionuclide MUGA OR
  • Fractional shortening ≥ 27% by echocardiogram


  • Normal lung function defined as no dyspnea at rest and no oxygen requirement OR measured oxygen saturation > 93% on room air


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No disease of any major organ system that would preclude study compliance
  • No concurrent hemodialysis
  • No active infection requiring IV antivirals, antibiotics, or antifungals (patients on antifungal therapy are eligible provided they are culture- and biopsy-negative in suspected residual radiographic lesions)
  • Patient weight within limits to receive ≤ maximum total allowable dose of ^131I-MIBG


Biologic therapy

  • No prior myeloablative transplantation

    • Prior submyeloablative transplantation allowed at discretion of principal investigator
  • More than 3 weeks since prior biologic therapy


  • More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for mitomycin C or nitrosoureas)
  • No prior melphalan therapy with a total dose of > 100 mg/m^2


  • See Disease Characteristics
  • At least 6 weeks since prior radiotherapy (6 months for craniospinal or whole lung radiotherapy)
  • No prior total body irradiation
  • No prior iodine I 131 MIBG (^131I-MIBG)
  • No prior total abdominal or whole liver radiotherapy
  • No prior local radiotherapy, including any of the following:

    • 1200 cGy to more than 33% of both kidneys (patient must have at least one kidney that has not exceeded the dose/volume of radiation listed)
    • 1800 cGy to more than 30% of liver and/or 900 cGy to more than 50% of liver


  • Recovered from all prior therapy
  • No medications with a potential interference of ^131I-MIBG uptake 1 week before and 2 weeks after completion of ^131I-MIBG
1 Year to 29 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
CDR0000450148, P01CA081403, N2001-02
Not Provided
Not Provided
Nant Operations Center, Children's Hospital Los Angeles
Children's Hospital Los Angeles
National Cancer Institute (NCI)
Study Chair: Gregory Yanik, MD University of Michigan Cancer Center
Principal Investigator: Katherine K. Matthay, MD University of California, San Francisco
Principal Investigator: John M. Maris, MD Children's Hospital of Philadelphia
Children's Hospital Los Angeles
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP